CLA (Conjugated Linoleic Acid): Dose, Label Math and Safety Notes

By Erin Rose · Updated July 20, 2026 · Methodology

Educational overview — not medical advice. Several trials reported metabolic changes with CLA in people with obesity, metabolic syndrome, or diabetes — see the safety section below. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

As an Amazon Associate we earn from qualifying purchases. Ranked by disclosed active CLA and cost, never commissions.

Start here

What CLA is (and the gap between animal and human data)

Conjugated linoleic acid is a group of naturally occurring fatty-acid isomers found in beef and dairy, sold as a supplement in concentrated form — usually a roughly 50:50 blend of the cis-9,trans-11 and trans-10,cis-12 isomers derived from safflower oil. Its reputation comes almost entirely from animal and cell studies, where CLA (especially the trans-10,cis-12 isomer) reduced body fat in mice and livestock. Human trials have not matched that. Two independent meta-analyses of human randomized controlled trials reported small effects: Whigham 2007 pooled 18 RCTs and reported a dose-response change in fat mass of about 0.09 kg/week versus placebo at the 3.2 g/day median dose (P<0.001), linear to about 6 months and then plateauing toward an asymptote by 2 years. Onakpoya 2012 pooled 7 longer-term RCTs and found a statistically significant but small 1.33 kg fat-mass difference favoring CLA, concluding in its own words that "the magnitude of these effects is small, and the clinical relevance is uncertain."

What the research shows (the short version)

Small effects on body composition, and a catch most marketing leaves out. The effects were small and plateaued rather than compounding. The catch: several well-controlled trials found CLA supplementation — particularly the isolated trans-10,cis-12 isomer, but in at least one trial also a standard 50:50 blend — worsened insulin sensitivity and raised fasting glucose, measured directly in obese, metabolic-syndrome, or type-2-diabetic participants (Risérus 2002; Moloney 2004) — and lowered HDL cholesterol in Risérus 2002 (though Moloney 2004 saw HDL rise, so the HDL signal isn't universal).

The buying and safety problem

Retail CLA products routinely under-dose relative to the ~3.2 g/day studied median: many softgels are 800-1,250 mg, so reaching a trial-relevant dose takes 3-4+ softgels a day, not the "take 1" a label photo implies — see the real cost-per-gram math on best CLA. On safety, the headline risks are insulin resistance/impaired glucose metabolism, reduced HDL cholesterol, and increased inflammation/oxidative stress — all measured directly in human trials, not theoretical — plus common GI upset and two rare but severe hepatotoxicity case reports (one requiring a liver transplant). Anyone with diabetes, prediabetes, or metabolic syndrome has the most reason for caution, precisely because that is the population the adverse glucose/insulin signal was measured in.

Frequently asked questions

Related guides

• MCT Oil — another supplement with its own research summary
• L-Carnitine — another supplement, with its own research summary
• Berberine — another supplement, with its own trade-offs
• Glucomannan — a fiber-based supplement
• Chromium — another mineral supplement
• Alpha-Lipoic Acid — an antioxidant that contrasts with CLA's oxidative-stress signal

Sources